Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression

Pharmacogenetics and Genomics

Volumn 22, Issue 5, 2012, Pages 381-388

  Benito, Rocío ^a   Lumbreras, Eva ^a   Abáigar, María ^a   Gutiérrez, Norma C ^b   Delgado, Manuel ^b   Robledo, Cristina ^a   García, Juan L ^b   Rodríguez Vicente, Ana E ^a   Cañizo, M Consuelo ^b   Rivas, Jesús Maria Hernández ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

chronic myeloid leukemia; DNA repair; gene expression; imatinib mesylate

Indexed keywords

BETA2 INTEGRIN; CD38 ANTIGEN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 6; CYCLIN E; CYTOCHROME C; FANCONI ANEMIA GROUP D2 PROTEIN; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; IMATINIB; INTERLEUKIN 1ALPHA; MITOFUSIN 2; MRE11 PROTEIN; NUCLEOPHOSMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN CDC42; PROTHYMOSIN ALPHA; RAD50 PROTEIN; RAD51 PROTEIN; REACTIVE OXYGEN METABOLITE; REPLICATION FACTOR C; RETINOIC ACID RECEPTOR ALPHA; S PHASE KINASE ASSOCIATED PROTEIN 2; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FKHRL1; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW CELL; CANCER CHEMOTHERAPY; CELL CYCLE PROGRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84863395953     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328351f3e9     Document Type: Article

References (50)

1. Jagani Z, Singh A, Khosravi-Far R. FoxO tumor suppressors and BCR-ABLinduced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta 2008; 1:63-84. (Pubitemid 350192084)
2. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 4944:824-830.
3. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 11:4010-4022. (Pubitemid 38685338)
4. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995; 1:307-313.
5. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997; 20: 6151-6161. (Pubitemid 27458335)
6. Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol 1991; 2:1107-1113. (Pubitemid 21895462)
7. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996; 3: 811-820. (Pubitemid 26113953)
8. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 1998; 7:968-981. (Pubitemid 28204604)
9. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 2: 189-218. (Pubitemid 38240034)
10. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 14:1031-1037. (Pubitemid 32267972)
11. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti- Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia 1. N Engl J Med 2002; 9: 645-652. (Pubitemid 34815868)
12. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study 5. Blood 2002; 10:3530-3539. (Pubitemid 34534519)
13. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 5:561-566.
14. Gambacorti-Passerini C, Bertazzoli C, Dermime S, Scardino A, Schendel D, Parmiani G. Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers 1. Clin Cancer Res 1997; 5:675-683. (Pubitemid 27244333)
15. Haferlach T, Kohlmann A, Schnittger S, Dugas M, Hiddemann W, Kern W, et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005; 4:1189-1198. (Pubitemid 41130867)
16. Yong AS, Melo JV. The impact of gene profiling in chronic myeloid leukaemia 1. Best Pract Res Clin Haematol 2009; 2:181-190.
17. Schmidt S, Gastl G, Wolf D. Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia 1. Leuk Lymphoma 2008; 4:643-647. (Pubitemid 351517204)
18. Crossman LC, Mori M, Hsieh YC, Lange T, Paschka P, Harrington CA, et al. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures 4. Haematologica 2005; 4:459-464. (Pubitemid 40598077)
19. De LH, Finetti P, Carbuccia N, Khorashad JS, Charbonnier A, Foroni L, et al. A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia 1. Leuk Res 2010; 2:254-257.
20. Frank O, Brors B, Fabarius A, Li L, Haak M, Merk S, et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia 2006; 8:1400-1407. (Pubitemid 44084053)
21. Kaneta Y, Kagami Y, Katagiri T, Tsunoda T, Jin-nai I, Taguchi H, et al. Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis 1. Jpn J Cancer Res 2002; 8:849-856. (Pubitemid 35012244)
22. McLean LA, Gathmann I, Capdeville R, Polymeropoulos MH, Dressman M. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib 2. Clin Cancer Res 2004; 1 (Pt 1):155-165. (Pubitemid 38114174)
23. Ohno R, Nakamura Y. Prediction of response to imatinib by cDNA microarray analysis 1. Semin Hematol 2003; 2 (Suppl 2):42-49.
24. Villuendas R, Steegmann JL, Pollan M, Tracey L, Granda A, Fernandez-Ruiz E, et al. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia 2006; 6:1047-1054. (Pubitemid 43797296)
25. Hakansson P, Lassen C, Olofsson T, Baldetorp B, Karlsson A, Gullberg U, et al. Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR/ABL expression reveals upregulation of CEACAM1 (CD66a). Leukemia 2004; 3:538-547. (Pubitemid 38425869)
26. Tipping AJ, Deininger MW, Goldman JM, Melo JV. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol 2003; 11:1073-1080. (Pubitemid 37329751)
27. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 8:1619-1630.
28. Gutierrez NC, Lopez-Perez R, Hernandez JM, Isidro I, Gonzalez B, Delgado M, et al. Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 2005; 3:402-409. (Pubitemid 40403317)
29. Sanchez-Guijo FM, Hernandez JM, Lumbreras E, Morais P, Santamaria C, Garcia JL, et al. Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response. Leuk Res 2009; 1:170-173.
30. Chen J, Schmitt A, Giannopoulos K, Chen B, Rojewski M, Dohner H, et al. Imatinib impairs the proliferation and function of CD4+CD25+ regulatory cells in a dose-dependent manner. Int J Oncol 2007; 5:1133-1139.
31. Nunoda K, Tauchi T, Takaku T, Okabe S, Akahane D, Sashida G, et al. Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors. Oncogene 2007; 28:4179-4188. (Pubitemid 46920165)
32. Li Y, Pei J, Xia H, Ke H,Wang H, Tao W. Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene 2003; 28:4398-4405. (Pubitemid 36897970)
33. Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 2004; Pt 2:297-309. (Pubitemid 38788101)
34. Komatsu N, Watanabe T, Uchida M, Mori M, Kirito K, Kikuchi S, et al. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. J Biol Chem 2003; 8:6411-6419. (Pubitemid 36800899)
35. Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-kinase/AKT pathway. J Biol Chem 2000; 50: 39223-39230. (Pubitemid 32058940)
36. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 8:4240-4245. (Pubitemid 29190320)
37. Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res 2001; 1:29-41. (Pubitemid 32989079)
38. Fu Z, Tindall DJ. FOXOs, cancer and regulation of apoptosis. Oncogene 2008; 16:2312-2319. (Pubitemid 351501782)
39. Birkenkamp KU, Coffer PJ. FOXO transcription factors as regulators of immune homeostasis: molecules to die for? J Immunol 2003; 4: 1623-1629. (Pubitemid 36966442)
40. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska- Skorska M, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 1:319-327. (Pubitemid 43990645)
41. Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene 2003; 25:3952-3963. (Pubitemid 36819669)
42. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 4:795-806. (Pubitemid 33030213)
43. Skorski T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 2002; 56:8591-8604. (Pubitemid 36084192)
44. Richardson C, Stark JM, Ommundsen M, Jasin M. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 2004; 2:546-553. (Pubitemid 38175009)
45. Arnaudeau C, Rozier L, Cazaux C, Defais M, Jenssen D, Helleday T. RAD51 supports spontaneous non-homologous recombination in mammalian cells, but not the corresponding process induced by topoisomerase inhibitors. Nucleic Acids Res 2001; 3:662-667. (Pubitemid 32124376)
46. Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K, et al. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 2003; 21:7377-7383. (Pubitemid 37413479)
47. Deutsch E, Jarrousse S, Buet D, Dugray A, Bonnet ML, Vozenin-Brotons MC, et al. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 2003; 11:4583-4588. (Pubitemid 36857831)
48. Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004; 12:3746-3753. (Pubitemid 39564453)
49. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T, et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000; 32:24273-24278. (Pubitemid 30626515)
50. Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010; 15:3109-3117.